Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
Small molecule deal activity exploded from zero to 70 transactions in six months — a 7000% surge that represents the sharpest modality-level acceleration we've tracked in 2026. Here's what's behind it, who's buying, and what it means for your next term sheet.
Mega-deal activity surged 6100% in the first half of 2026 — from zero transactions to 61 in six months. Eli Lilly alone accounted for nearly $5B in total deal value across two mega-deals licensing 2026 transactions in a single week.
Deals classified outside traditional therapeutic categories surged 3900% in the first half of 2026, jumping from zero to 39 transactions. The Merck KGaA–Bio-Techne mega-deal and Pfizer's YaoPharma partnership signal a structural shift in how pharma is sourcing value.
Mega-deal activity exploded from zero to 61 transactions in six months — a 6100% increase that rewrites the biopharma licensing landscape. Eli Lilly alone accounted for $4.7B in total deal value across two transactions in a single week. Here's what's driving it, who's winning, and what BD teams should do right now.
Mega-deal activity surged 6100% in the first half of 2026, with 61 transactions recorded after a complete shutout in the prior six months. Eli Lilly alone accounted for two deals exceeding $2B in total deal value within a single week. Here's what's behind the shift and what it means for your next negotiation.
Other deal activity exploded from zero to 39 transactions in the first half of 2026 — a 3900% increase. The Merck KGaA–Bio-Techne mega-deal and Pfizer's YaoPharma licensing agreement are reshaping how BD teams think about platform acquisitions and cross-border deals outside traditional therapeutic silos.
Mega-deal activity jumped from zero to 61 transactions in six months — a 6100% increase that signals a fundamental shift in how Big Pharma is filling pipeline gaps. Here's what's driving it and what it means for your next negotiation.
Small molecule licensing activity exploded 3067% in the first half of 2026, jumping from 3 deals to 95. Big Pharma patent cliffs, Chinese biotech exports, and a renewed appetite for oral therapeutics are converging into the most aggressive small molecule deal environment in a decade.
Rare disease deal activity exploded from 1 transaction to 34 in six months — a 3300% increase. Five deals alone represent over $11B in total deal value, signaling a structural shift in how pharma is filling pipeline gaps in orphan indications.
Deal activity in the 'other' category — platform technology, tools, and non-traditional licensing — exploded by 3900% in the first half of 2026. Bio-Techne's $11.3B tie-up with Merck KGaA and Novartis's move on Generate:Biomedicines signal that pharma's appetite has shifted beyond molecules to the infrastructure that creates them.
Sixty-one mega-deals closed between January and July 2026 after a complete shutout in the prior six months — a 6100% spike that rewrites the competitive landscape. Here's what's driving it, who's buying, and what BD teams should do right now.
39 deals closed in the first half of 2026 in categories that defy traditional therapeutic area classification — up from zero in the prior six months. The Bio-Techne/Merck KGaA $11.3B acquisition and Pfizer's $2B+ YaoPharma partnership are reshaping how BD teams think about platform-level dealmaking.
Mega-deal activity exploded from zero to 61 transactions in six months — a 6100% increase that signals a fundamental shift in how Big Pharma is filling pipeline gaps. Here's the data, the drivers, and what BD teams should do about it right now.
Peptide licensing activity exploded 1200% period-over-period in the first half of 2026, jumping from 1 deal to 13. Biogen's $5.6B Apellis acquisition and Lilly's Hanmi tie-up define the new competitive dynamics. Here's what it means for your next negotiation.
Hematology deal activity exploded from zero to 16 transactions in the first half of 2026 — a 1600% surge driven by Big Pharma pipeline anxiety and a $2B mega-deal from Incyte. Here's what the data says and what it means for your next negotiation.
Vaccine deal activity exploded from zero transactions to 17 in six months — a 1700% surge that signals a fundamental repricing of vaccine assets. Eli Lilly alone anchored multiple deals exceeding $2B in total deal value. Here's what's driving it and what it means for your next negotiation.
Deal activity in the 'other' modality category surged 1860% in six months — from 5 deals to 98. Mega-deals from Novo Nordisk, AstraZeneca, and Novartis reveal a strategic land-grab in non-traditional modalities that BD teams can no longer afford to treat as edge cases.
ADC licensing activity exploded by 1900% in the first half of 2026, jumping from 1 deal to 20 in six months. GSK, Novartis, and Whitehawk are leading the charge. Here's what's driving it and what BD teams need to do right now.
Twenty bispecific antibody deals closed between January and July 2026 — up from zero in the prior six months. Pfizer alone committed $2.5B in upfront payments across two 3SBio transactions. Here's what's driving the surge and what it means for your next negotiation.
Small molecule deal activity exploded 3067% in the first half of 2026, jumping from 3 deals to 95. The surge is reshaping small molecule licensing 2026 dynamics — here's what's driving it and what BD teams need to do now.
Rare disease licensing went from 1 deal to 34 in six months — a 3300% increase that's reshaping BD strategy across pharma. We analyze the drivers, the marquee transactions, and the tactical implications for buyers and sellers.
Forty deals in six months versus zero in the prior half — other deal trends 2026 represent the most dramatic category shift we've tracked. Merck KGaA's $11.3B Bio-Techne acquisition and Pfizer's $2B YaoPharma licensing deal reveal why pharma is hunting outside traditional therapeutic silos.
Mega-deal activity surged 6100% in the first half of 2026 — from zero transactions to 61 in six months. Eli Lilly alone accounted for nearly $5B in total deal value across two deals in a single week. Here's what's driving it and what BD teams should do now.
Mega-deal activity exploded from zero to 61 transactions in the first half of 2026 — a 6100% increase. Eli Lilly alone accounted for multiple billion-dollar-plus licensing plays in a single week. Here's what the data says and what it means for your next negotiation.
Oligonucleotide licensing 2026 exploded from 1 deal to 25 in six months — a 2400% increase. The Arrowhead–Sarepta $10B TDV megadeal anchors a wave that's reshaping deal structures and valuations across the modality.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.
Try Solidus
